ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) gene rearrangements occur in 3% to 5% of patients with non-small cell lung cancer (NSCLC) and confer sensitivity to treatment with ALK tyrosine kinase inhibitors (TKIs) [1,2].